AI SummaryThis study explores the use of gene editing for latent herpes simplex virus infection, aiming to reduce viral load and shedding in vivo. The research focuses on using HSV-specific meganucleases delivered by adeno-associated virus vectors to eliminate latent HSV DNA in mouse models of infection. Results show a significant reduction in viral shedding with… Continue reading Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo
Tag: Diagnostic and Laboratory Virology
TWiV 1112: Clinical update with Dr. Daniel Griffin
AI SummaryDr. Griffin provides a clinical update focusing on infections in dairy cattle, the effectiveness of known anti-influenza antivirals, recent statistics on SARS-CoV-2 infections, guidelines for COVID vaccine boosters, the association between boosters and long COVID, pre-exposure prophylactic use, preventing post-acute sequelae with oral antiviral therapies, dispelling the myth of viral rebound, steroid usage, convalescent… Continue reading TWiV 1112: Clinical update with Dr. Daniel Griffin
Nonlinear relationship between viral load and TCT in single/multiple HPV52 infection
AI SummaryThe content discusses the nonlinear relationship between the viral load of HPV52, multiple infections, and ThinPrep cytology test (TCT) results. The aim is to provide valuable information for the clinical management of women who test positive for HPV52 after cervical cancer screening. The research likely delves into how varying levels of viral load and… Continue reading Nonlinear relationship between viral load and TCT in single/multiple HPV52 infection
Cholinergic Control of GnRH Neuron Physiology and Luteinizing Hormone Secretion in Male Mice: Involvement of ACh/GABA Cotransmission
AI SummaryThis article discusses the role of the cholinergic system in regulating Gonadotropin-releasing hormone (GnRH) neurons and luteinizing hormone (LH) secretion in male mice. The study reveals that activation of the cholinergic system increases LH secretion and that GnRH neurons are innervated by cholinergic axons originating from specific brain regions. The cholinergic neurotransmission has biphasic… Continue reading Cholinergic Control of GnRH Neuron Physiology and Luteinizing Hormone Secretion in Male Mice: Involvement of ACh/GABA Cotransmission
P01.07 Intracellular and extracellular biochemical activities of V-domain Ig-containing suppressor of T cell activation or VISTA
AI SummaryThe content discusses the intracellular and extracellular biochemical activities of V-domain Ig-containing suppressor of T cell activation (VISTA). The article presents findings about how VISTA acts as a ligand on T cell surfaces to suppress granzyme B-dependent cytotoxic activities. Additionally, the research identifies the T-cell associated signaling receptor that recognizes VISTA as a ligand… Continue reading P01.07 Intracellular and extracellular biochemical activities of V-domain Ig-containing suppressor of T cell activation or VISTA
P01.01 Isoliquiritigenin attenuated metastatic development of pancreatic cancer by regulation of the tumor microenvironment and reactivation from chemoresistance
AI SummaryThe study explores how isoliquiritigenin (ISL), a flavonoid present in licorice, can inhibit metastatic development in pancreatic cancer by regulating the tumor microenvironment and reversing chemoresistance to gemcitabine. ISL was found to inhibit migratory activity and invasiveness of pancreatic cancer cells, decrease expression of pro-metastatic biomarkers, increase ROS levels, modulate immune cell populations in… Continue reading P01.01 Isoliquiritigenin attenuated metastatic development of pancreatic cancer by regulation of the tumor microenvironment and reactivation from chemoresistance
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
AI SummaryThe study assessed the safety and efficacy of nivolumab in people living with HIV (PLWH) with advanced cancer on antiretroviral therapy. Participants received nivolumab every 2 weeks, with no dose-limiting toxicities observed. Some patients had immune-related adverse events, and there were objective partial responses in 25% of participants, with a longer duration of response… Continue reading Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study
Cycle threshold of SARS-CoV-2 RT-PCR as a driver of retesting
Abstract SARS-CoV-2 RT-PCR is a critical and, at times, limited resource. Frequent Retesting of patients may strain testing infrastructure unduly. Recommendations that include cycle threshold (Ct) cutoffs may incentivize early retesting when the Ct value is reported. We aimed to investigate patterns of retesting in association with initial Ct-values. We performed a retrospective analysis of… Continue reading Cycle threshold of SARS-CoV-2 RT-PCR as a driver of retesting
HIV: Early treatment, one key to remission
People living with HIV need to take antiretroviral treatment for life to prevent the virus from multiplying in their body. But some people, known as ‘post-treatment controllers,’ have been able to discontinue their treatment while maintaining an undetectable viral load for several years. Starting treatment early could promote long-term control of the virus if treatment… Continue reading HIV: Early treatment, one key to remission
897-G SR-8541A, a small molecule inhibitor of ENPP1, enhances the effect of immune checkpoint inhibitors in a colorectal cancer model
Background The five-year survival rate for colorectal cancer (CRC) remains at 14% despite improvements in early detection and development of novel treatments, including immune checkpoint inhibitors (ICIs). The immune landscape of CRC is heterogeneous and complex, posing challenges in treatment decision-making.1 2 Colorectal tumors presenting with microsatellite stable (MSS) or mismatch repair proficiency (MMRP) account… Continue reading 897-G SR-8541A, a small molecule inhibitor of ENPP1, enhances the effect of immune checkpoint inhibitors in a colorectal cancer model